On February 19, 2024, Gain Therapeutics, Inc. received notice of the resignation of C. Evan Ballantyne as the Company's Chief Financial Officer, and all other positions held at the Company, to be effective March 1, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.55 USD | +1.59% | +5.37% | -21.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.90% | 46.03M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.
- Gain Therapeutics, Inc. Announces the Resignation of C. Evan Ballantyne as Chief Financial Officer, Effective March 1, 2024